Core Viewpoint - Dentsply International (XRAY) is expected to report a decline in quarterly earnings and revenues, with analysts predicting earnings of $0.43 per share, a decrease of 2.3% year-over-year, and revenues of $919.36 million, reflecting a 9.2% decline compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating that analysts have not revised their initial projections during this period [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Net sales- Connected Technology Solutions' to be $296.59 million, representing a year-over-year decline of 7% [5]. - 'Net sales- Wellspect Healthcare' is projected to reach $76.04 million, indicating a slight increase of 0.1% from the same quarter last year [5]. - 'Net sales- Essential Dental Solutions' is expected to be $337.26 million, reflecting a decrease of 5.8% year-over-year [6]. - 'Net sales- Orthodontic and Implant Solutions' is forecasted at $207.43 million, showing a significant decline of 19.9% compared to the prior year [6]. - 'Revenues- Rest of World' is projected to be $205.38 million, indicating a year-over-year decrease of 16.9% [6]. - 'Revenues- Europe' is expected to come in at $368.16 million, reflecting a decline of 7.3% year-over-year [7]. Stock Performance - Over the past month, Dentsply shares have recorded a return of -2.9%, compared to a -1.8% change in the Zacks S&P 500 composite [7]. - Based on its Zacks Rank 4 (Sell), Dentsply is likely to underperform the overall market in the upcoming period [7].

Core Viewpoint - DENTSPLY SIRONA Inc. is set to release its fourth-quarter 2024 results on February 27, with expectations of weaker sales and ongoing market challenges, particularly due to the suspension of Byte sales and regulatory issues [1][10]. Group 1: Financial Estimates - The Zacks Consensus Estimate for revenues in Q4 is $919.4 million, while the consensus for earnings is 43 cents per share [3]. - The company has lowered its full-year revenue guidance to a range of $3.79 billion to $3.82 billion, with an adjusted EBITDA margin expected to be around 17.5% [10]. Group 2: Segment Performance - The Orthodontic and Implant Solutions segment experienced a revenue decline due to the suspension of Byte sales, which is anticipated to result in a $40 million revenue loss [4]. - SureSmile showed year-on-year growth, particularly in Europe and the Rest of World, but faced weaker demand in the United States [5]. - The Connected Technology Solutions segment's performance declined, although CAD/CAM sales grew due to strong demand for mills and intraoral scanners [6]. - The Essential Dental Solutions segment saw significant organic growth, supported by early distributor orders and strong performance in China and Canada [7]. Group 3: Product Developments - The company launched several new products, including the Primescan 2 intraoral scanner and the X-Smart Pro+ endo motor, which have contributed positively to sales [8][9]. - Regulatory approval was received for five new products, and the software platform DS Core was improved with over 85 updates [9]. Group 4: Market Outlook - The company expects organic sales to decline in the high-single digits for Q4, primarily due to the Byte sales suspension and weak equipment demand in the U.S. [4]. - Despite challenges, the company plans to invest more in SureSmile orthodontics software and other digital tools to support future growth [9].

Dentsply International (XRAY) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 27, 2025, might help the stock move higher if these key numbers are ...

CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company has initiated a process to evaluate strategic alternatives for its Wellspect Healthcare business (“Wellspect”). Wellspect is a leading provider of bladder and bowel management care products with an over 40-year history. Through its comprehensive portfolio of products and accessories from trusted brands like LoFric® and Navina™, Wellspect has delivered i ...

NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DENTSPLY SIRONA Inc. (NASDAQ:XRAY) on behalf of long-term stockholders following a class action complaint that was filed against Dentsply on November 26, 2024 with a Class Period from May 6, 2021 to November 6, 2024. Our investigation concerns whether the board of directors of Dentsply have breached their fiduciary duties to the company. The ...

CHARLOTTE, N.C., Jan. 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, February 27, 2025, at 8:30 am ET to review its fourth quarter and full year 2024 financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A ...

RADNOR, Pa., Jan. 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Southern District of New York against DENTSPLY SIRONA Inc. (“DENTSPLY”) (NASDAQ: XRAY) on behalf of those who purchased or otherwise acquired DENTSPLY common stock between May 6, 2021, and November 6, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is January 27, 2 ...

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Dentsply Sirona Inc. ("Dentsply" or the "Company") (NASDAQ: XRAY) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Dentsply investors who were adversely affected by alleged securities fraud between May 6, 2021 and November 6, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/dentsply-lawsuit-submission-fo ...

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Dentsply Sirona Inc. (NASDAQ: XRAY) between May 6, 2021 and November 6, 2024, both dates inclusive (the “Class Period”), of the important January 27, 2025 lead plaintiff deadline. SO WHAT: If you purchased Dentsply Sirona common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Dentsply To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Dentsply between February 28, 2022 and November 6, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Jan. 23, 2025 /PRNewswire/ -- Faruqi & F ...